参考文献/References:
[1] Wadkins RM,Roepe PD. Biophysical aspects of P-glycoprotein-mediated multidrug resistance[J].Int Rev Cytol,1997,171:121-165.
[2] Eytan GD,Kuchel PW. Mechanism of action of P-glycoprotein in relation to passive membrane permeation[J].Int Rev Cytol,1999,190:175-250.
[3] Schinkel AH,Borst P. Multidrug resistance mediated by P-glycoproteins[J].Semin Cancer Biol,1991,2:213-226.
[4] Mahmond A,Ahmed A,Robert SM, et al. P-glycoprotein as a prognostic indicator in pre-and post-chemotherapy ovarian adenocarcinoma[J].Int J Gyne Pathol,1997,16:69-75.
[5] Kelly MK,Engqviest-Goldstein A,Montali JA, et al. Variability of glutathione S-transferase isoenzyme patterns in patched normal and cancer human breast tissue[J].Biochem J,1994,304:843.
[6] Fan KC,Huang YC,Li CH, et al. Radioimmunoassay for plasma glutathione S-transfase pi and its clinical application in gastrointestinal cancer[J].Cancer,1995,1364-1367.
[7] HidaT,Kuwabara M,Ariyoshi Y, et al. Serum glutathione S-transferase-pi level as a tumor marker for non-small cell lung cancer.Potential predictive value in chemotherapeutic response[J].Cancer,1994,73(5):1377-1382.
[8] Bai F,Nakanishi Y,Kawasaki M, et al. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma[J].Cancer,1996,78(3):416-421.
[9] Petrini M,Simone DD,Favati A, et al. GST-π and P-170 coexpression in multiple myeloma[J].Br J Haematol,1995,90:393.
[10] Bossanyi PV,Diete S,Dietzmann K, et al. Immunohistochemical expression of P-glycoprotein and glutathione Stransferase in cerebal gliomas and response to chemotherapy[J].Acta Neuropathol,1997,94(6):605-611.
[11] Russo D,Marie JP,Zhou DC, et al. Coexpression of anionic glutathione-S-transferase(GST pi) and multidrug resistance(mdr1)genes in acute myeloid and lymphoid leukemias[J].Leukemia,1994,8(5):881-884.
[12] Weissenberger C,Fiebig HH,Lutterbach J, et al. Is there any correlation between MDR1,GST-pi-expression and CEA[J].Anticancer Res,2000,20(6):5139-5144.
[13] Monden N,Abe S,Sutoh I, et al. Prognostic significance of the expressions of metallothionein,glutathione-S-transferase-pi,and P-glycoprotein in curatively resected gastric cancer[J].Oncology,1997,54(5):391-399.
[14] Muriel JL,Cordobest D,Statrzec A, et al. Technetium 99m-sestamibi uptake by humman benign and malignant breast turmor cells:correlation with gene expression[J].J Nucl Med,1996,37:286-288.
[15] Kostakoglu L,Elahi N,Kiratli P, et al. Clin validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors[J].J Nucl Med,1997,38(7):1003-1008.
[16] Vecchio SD,Ciarmiello A,Leonardo Pace, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients[J].J Nucl Med,1997,38(9):1348-1351.
[17] Chia-Hung Kao,Shih-Chuan T,sai Liu TG, et al. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings[J].Cancer Res,2001,15(61):1412-1414.
[18] Muriel A,Noreli F,Jean-Marc R, et al. Enhancement of mdrl gene expression in normal tissue adjacent to advanced breast cancer[J].Breast Cancer Res Trea,2000,61(1):13-20.
[19] Xiaowei Y,Beatrice U,Susan U, et al. MDR1 gene expression in primary and advanced breast Cancer[J].Laboratory Investigation,1999,79(3):271-280.
[20] Kabasakal L,Ozker K,Hayward M, et al. Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance[J].Eur J Nucl Med,1996,23(5):568-570.
[21] Kostakoglu L,Ruacan S,Ergun EL, et al. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer[J].J Nucl Med,1998,39(6):1021-1026.